Enanta (ENTA) Worth Watching: Stock Rises 13.4% - Tale of the Tape

Enanta Pharmaceuticals, Inc. (ENTA) was a big mover last session with its shares rising over 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company, as the stock is now up nearly 27% in the past one-month time frame.
 
This biotechnology company has seen no estimate revision in the last 7 days. However, the Zacks Consensus Estimate has moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if Friday’s rally can turn into more strength down the road.

Enanta Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Some better-ranked retail stocks include Lannett Company, Inc. (LCI), Endocyte, Inc. (ECYT) and BioCryst Pharmaceuticals, Inc. (BCRX). While LCI and ECYT sport a Zacks Rank #1 (Strong Buy), BCRX carries a Zacks Rank #2 (Buy).  

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

BIOCRYST PHARMA (BCRX): Free Stock Analysis Report

ENDOCYTE INC (ECYT): Free Stock Analysis Report

ENANTA PHARMA (ENTA): Free Stock Analysis Report

LANNETT INC (LCI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research